phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide has been researched along with Carcinoma, Small Cell in 1 studies
phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide: cyclic somatostatin octapeptide analog with high affinity & selectivity toward mu opioid receptors
Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zamora, PO | 1 |
| Bender, H | 1 |
| Knapp, FF | 1 |
| Rhodes, BA | 1 |
| Biersack, HJ | 1 |
1 other study available for phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide and Carcinoma, Small Cell
| Article | Year |
|---|---|
Targeting peptides for pleural cavity tumor radiotherapy: specificity and dosimetry of Re-188-RC-160.
Topics: Animals; Antineoplastic Agents; Carcinoma, Small Cell; Drug Delivery Systems; Half-Life; Humans; Lun | 1997 |